Modeling tumor relapse using proliferation tracing and ablation transgenic mouse

Abstract Tumor relapse remains a significant obstacle to successful therapy. Preclinical animal models that accurately reflect tumor relapse in patients are urgently needed. Here, we employed a dual recombinase-mediated genetic system to genetically trace and ablate proliferating cells in a polyomav...

Full description

Saved in:
Bibliographic Details
Main Authors: Chuang Zhao, Xin-nan Zheng, Han-ying Huang, Lin Tian
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-025-00792-1
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849234705867603968
author Chuang Zhao
Xin-nan Zheng
Han-ying Huang
Lin Tian
author_facet Chuang Zhao
Xin-nan Zheng
Han-ying Huang
Lin Tian
author_sort Chuang Zhao
collection DOAJ
description Abstract Tumor relapse remains a significant obstacle to successful therapy. Preclinical animal models that accurately reflect tumor relapse in patients are urgently needed. Here, we employed a dual recombinase-mediated genetic system to genetically trace and ablate proliferating cells in a polyomavirus middle T antigen (PyMT)-induced spontaneous murine breast cancer model. This system enabled the acute ablation of cells that had undergone proliferation within a defined time window, resulting in a drastic tumor shrinkage, followed by a gradual tumor relapse due to the presence of residual low-cycling cells. We then applied single-cell RNA sequencing (scRNA-seq) to unbiasedly compare the tumor ecosystems of the primary and relapsed PyMT tumors. Compared with the primary tumors, the relapsed tumors exhibited a higher proportion of cancer stem cells and pro-tumor γδ T cells, as well as co-expression of Spp1 and Vegfa in multiple myeloid cell populations – features that predict poor therapeutic response and unfavorable outcomes in human breast cancer patients. Collectively, this proliferation tracing and ablation model emulates chemotherapies that preferentially eliminate proliferating cancer cells, serving as a robust tool and a valuable resource for testing novel therapeutic strategies in relapsed tumors.
format Article
id doaj-art-a0562741579f4860b04bb60f44c81dbd
institution Kabale University
issn 2374-4677
language English
publishDate 2025-07-01
publisher Nature Portfolio
record_format Article
series npj Breast Cancer
spelling doaj-art-a0562741579f4860b04bb60f44c81dbd2025-08-20T04:03:03ZengNature Portfolionpj Breast Cancer2374-46772025-07-0111111210.1038/s41523-025-00792-1Modeling tumor relapse using proliferation tracing and ablation transgenic mouseChuang Zhao0Xin-nan Zheng1Han-ying Huang2Lin Tian3State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer CenterAbstract Tumor relapse remains a significant obstacle to successful therapy. Preclinical animal models that accurately reflect tumor relapse in patients are urgently needed. Here, we employed a dual recombinase-mediated genetic system to genetically trace and ablate proliferating cells in a polyomavirus middle T antigen (PyMT)-induced spontaneous murine breast cancer model. This system enabled the acute ablation of cells that had undergone proliferation within a defined time window, resulting in a drastic tumor shrinkage, followed by a gradual tumor relapse due to the presence of residual low-cycling cells. We then applied single-cell RNA sequencing (scRNA-seq) to unbiasedly compare the tumor ecosystems of the primary and relapsed PyMT tumors. Compared with the primary tumors, the relapsed tumors exhibited a higher proportion of cancer stem cells and pro-tumor γδ T cells, as well as co-expression of Spp1 and Vegfa in multiple myeloid cell populations – features that predict poor therapeutic response and unfavorable outcomes in human breast cancer patients. Collectively, this proliferation tracing and ablation model emulates chemotherapies that preferentially eliminate proliferating cancer cells, serving as a robust tool and a valuable resource for testing novel therapeutic strategies in relapsed tumors.https://doi.org/10.1038/s41523-025-00792-1
spellingShingle Chuang Zhao
Xin-nan Zheng
Han-ying Huang
Lin Tian
Modeling tumor relapse using proliferation tracing and ablation transgenic mouse
npj Breast Cancer
title Modeling tumor relapse using proliferation tracing and ablation transgenic mouse
title_full Modeling tumor relapse using proliferation tracing and ablation transgenic mouse
title_fullStr Modeling tumor relapse using proliferation tracing and ablation transgenic mouse
title_full_unstemmed Modeling tumor relapse using proliferation tracing and ablation transgenic mouse
title_short Modeling tumor relapse using proliferation tracing and ablation transgenic mouse
title_sort modeling tumor relapse using proliferation tracing and ablation transgenic mouse
url https://doi.org/10.1038/s41523-025-00792-1
work_keys_str_mv AT chuangzhao modelingtumorrelapseusingproliferationtracingandablationtransgenicmouse
AT xinnanzheng modelingtumorrelapseusingproliferationtracingandablationtransgenicmouse
AT hanyinghuang modelingtumorrelapseusingproliferationtracingandablationtransgenicmouse
AT lintian modelingtumorrelapseusingproliferationtracingandablationtransgenicmouse